Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

Scott R. Daigle, Edward J. Olhava, Carly A. Therkelsen, Aravind Basavapathruni, Lei Jin, P. Ann Boriack-Sjodin, Christina J. Allain, Christine R. Klaus, Alejandra Raimondi, Margaret Porter Scott, Nigel J. Waters, Richard Chesworth, Mikel P. Moyer, Robert A. Copeland, Victoria M. Richon, Roy M. Pollock

Blood (2013) 122 (6): 1017–1025.

https://doi.org/10.1182/blood-2013-04-497644

Published: 2013

Includes: Supplemental data

Journal Articles

Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l

Aniruddha J. Deshpande, Liying Chen, Maurizio Fazio, Amit U. Sinha, Kathrin M. Bernt, Deepti Banka, Stuart Dias, Jenny Chang, Edward J. Olhava, Scott R. Daigle, Victoria M. Richon, Roy M. Pollock, Scott A. Armstrong

Blood (2013) 121 (13): 2533–2541.

https://doi.org/10.1182/blood-2012-11-465120

Published: 2013

Includes: Supplemental data

Journal Articles

MLL-AF6 Mediated Transformation Is Dependent On the H3K79 Methyl-transferase Dot1l

Aniruddha J Deshpande, Liying Chen, Maurizio Fazio, Amit U. Sinha, Kathrin M Bernt, MD, Deepti Banka, Stuart Dias, Edward J Olhava, PhD, Scott R Daigle, Victoria M Richon, PhD, Roy M Pollock, PhD, Scott A. Armstrong, MD, PhD

Blood (2012) 120 (21): 3502.

https://doi.org/10.1182/blood.V120.21.3502.3502

Published: 2012

Journal Articles

Preclinical Characterization of E7438, a Potent, Selective Inhibitor of Protein Methyltransferase EZH2 with Robust Antitumor Activity Against EZH2 Mutated Non-Hodgkin Lymphoma Xenografts in Mice

Blood (2012) 120 (21): 3712.

https://doi.org/10.1182/blood.V120.21.3712.3712

Published: 2012

Journal Articles

Preclinical Characterization of a Potent, Selective Inhibitor of the Protein Methyltransferase DOT1L for Use in the Treatment of MLL -Rearranged Leukemia.

Roy M Pollock, PhD, Scott R Daigle, Carly A Therkelsen, Aravind Basavapathruni, PhD, Lei Jin, PhD, Christina J Allain, Christine R Klaus, Alejandra Raimondi, PhD, Margaret Porter Scott, PhD, Richard Chesworth, DPhil, Mikel P Moyer, PhD, Robert A Copeland, PhD, Victoria M Richon, PhD, Edward J Olhava, PhD

Blood (2012) 120 (21): 2379.

https://doi.org/10.1182/blood.V120.21.2379.2379

Published: 2012

Journal Articles

Abrogation of MLL-AF10 and CALM-AF10 Mediated Transformation Through Genetic Inactivation or Pharmacological Inhibition of the H3K79 Methyltransferase DOT1L.

Liying Chen, Aniruddha J Deshpande, Deepti Banka, Bernt Kathrin, Stuart Dias, Christian Buske, MD, Edward J Olhava, PhD, Scott R Daigle, Victoria M Richon, PhD, Roy M Pollock, PhD, Scott A. Armstrong, MD, PhD

Blood (2012) 120 (21): 2384.

https://doi.org/10.1182/blood.V120.21.2384.2384

Published: 2012

Journal Articles

Demonstration of a Role for Dot1l In MLL -Rearranged Leukemia Using a Conditional Loss of Function Model

Kathrin M Bernt, MD, Nan Zhu, PhD, Joerg Faber, M.D., Natalie Punt, Roy M Pollock, PhD, Victoria M Richon, PhD, Andrew L. Kung, MD, PhD, Scott Armstrong, MD, PhD

Blood (2010) 116 (21): 62.

https://doi.org/10.1182/blood.V116.21.62.62

Published: 2010

Journal Articles

Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor

Roy M Pollock, PhD, Scott R Daigle, Edward J Olhava, PhD, Carly A Therkelsen, Christina R Majer, Jeffrey Song, Christina J Allain, Christopher J Sneeringer, L. Danielle Johnston, Margaret Porter Scott, PhD, Lei Jin, PhD, Kevin W Kuntz, PhD, Richard Chesworth, DPhil, Mikel P Moyer, PhD, Kathrin M Bernt, MD, Scott Armstrong, MD, PhD, Robert A Copeland, PhD, Victoria M Richon, PhD

Blood (2010) 116 (21): 780.

https://doi.org/10.1182/blood.V116.21.780.780

Published: 2010

Journal Articles

Lymphoma-Associated Mutations of EZH2 Result In a Change-of-Function

Victoria M Richon, PhD, Christopher J Sneeringer, MSc, Margaret Porter Scott, PhD, Kevin W Kuntz, PhD, Sarah K Knutson, PhD, Roy M Pollock, PhD, Robert A Copeland, PhD

Blood (2010) 116 (21): 707.

https://doi.org/10.1182/blood.V116.21.707.707

Published: 2010

Journal Articles

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Blood (2008) 111 (3): 1060–1066.

https://doi.org/10.1182/blood-2007-06-098061

Published: 2008

Includes: Supplemental data

Journal Articles

High Expression and Persistent Activation of STAT1, 3 and 5 Predicts Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Resistance in Cutaneous T-Cell Lymphoma Cells.

Valeria R. Fantin, PhD, Andrey Loboda, PhD, Jennifer A. Roth, Cloud Paweletz, PhD, Sophia Randolph, MD, PhD, Jacqueline W. Pierce, PhD, Elizabeth A. Harrington, PhD, Ronald C. Hendrickson, PhD, John F. Reilly, PhD, Christopher Ware, Marshall E. Kadin, MD, Madeleine Duvic, MD, Stanley R. Frankel, MD, Victoria M. Richon, PhD

Blood (2006) 108 (11): 4679.

https://doi.org/10.1182/blood.V108.11.4679.4679

Published: 2006

Journal Articles

Identification of Informative Gene Expression Signatures Indicative of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Exposure and Clinical Efficacy in Patients with Advanced Cutaneous T-Cell Lymphoma.

Andrey Loboda, PhD, Valeria Fantin, PhD, Sophia Randolph, MD, PhD, Justin L. Ricker, MD, PhD, James S. Hardwick, PhD, Victoria M. Richon, PhD, Stanley R. Frankel, MD

Blood (2006) 108 (11): 4686.

https://doi.org/10.1182/blood.V108.11.4686.4686

Published: 2006

Journal Articles

Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Clinical Benefit to Advanced Cutaneous T-Cell Lymphoma Patients: Updated Results of the Phase IIb Multicenter Clinical Trial.

Madeleine Duvic, MD, Youn H. Kim, MD, Timothy M. Kuzel, MD, Theresa R. Pacheco, MD, Francine M. Foss, MD, Sareeta Parker, MD, Stanley R. Frankel, MD, Cong Chen, PhD, Justin L. Ricker, MD, PhD, Jean Marie Arduino, PhD, Sophia Randolph, MD, PhD, Victoria M. Richon, PhD, Elise A. Olsen, MD

Blood (2006) 108 (11): 399.

https://doi.org/10.1182/blood.V108.11.399.399

Published: 2006

Journal Articles

Clinical Responses to Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Are Associated with Specific Gene Expression Signatures in Patients with Advanced Leukemias: Results of a Phase I Trial.

Andrey Loboda, PhD, Valeria R. Fantin, PhD, Carlos E. Bueso-Ramos, MD, PhD, Sophia Randolph, MD, PhD, James S. Hardwick, PhD, Justin L. Ricker, MD, PhD, Victoria M. Richon, PhD, Jean-Pierre Issa, MD, Hagop M. Kantarjian, MD, Stanley R. Frankel, MD, Guillermo Garcia-Manero, MD

Blood (2006) 108 (11): 2320.

https://doi.org/10.1182/blood.V108.11.2320.2320

Published: 2006

Journal Articles

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Madeleine Duvic, Rakshandra Talpur, Xiao Ni, Chunlei Zhang, Parul Hazarika, Cecilia Kelly, Judy H. Chiao, John F. Reilly, Justin L. Ricker, Victoria M. Richon, Stanley R. Frankel

Blood (2006) 109 (1): 31–39.

https://doi.org/10.1182/blood-2006-06-025999

Published: 2006

Journal Articles

Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor

Blanca Sanchez-Gonzalez, Hui Yang, Carlos Bueso-Ramos, Koyu Hoshino, Alfonso Quintas-Cardama, Victoria M. Richon, Guillermo Garcia-Manero

Blood (2006) 108 (4): 1174–1182.

https://doi.org/10.1182/blood-2005-09-008086

Published: 2006

Includes: Supplemental data

Journal Articles

Phase I Clinical Trial of Oral Administration of the Histone Deacetylase (HDAC) Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Relapsed/Refractory Multiple Myeloma (MM).

Blood (2004) 104 (11): 1503.

https://doi.org/10.1182/blood.V104.11.1503.1503

Published: 2004

Journal Articles

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

Nicholas Mitsiades, Constantine S. Mitsiades, Paul G. Richardson, Ciaran McMullan, Vassiliki Poulaki, Galinos Fanourakis, Robert Schlossman, Dharminder Chauhan, Nikhil C. Munshi, Teru Hideshima, Victoria M. Richon, Paul A. Marks, Kenneth C. Anderson

Blood (2003) 101 (10): 4055–4062.

https://doi.org/10.1182/blood-2002-11-3514

Published: 2003

NARROW

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l

MLL-AF6 Mediated Transformation Is Dependent On the H3K79 Methyl-transferase Dot1l

Preclinical Characterization of E7438, a Potent, Selective Inhibitor of Protein Methyltransferase EZH2 with Robust Antitumor Activity Against EZH2 Mutated Non-Hodgkin Lymphoma Xenografts in Mice

Preclinical Characterization of a Potent, Selective Inhibitor of the Protein Methyltransferase DOT1L for Use in the Treatment of MLL -Rearranged Leukemia.

Abrogation of MLL-AF10 and CALM-AF10 Mediated Transformation Through Genetic Inactivation or Pharmacological Inhibition of the H3K79 Methyltransferase DOT1L.

Demonstration of a Role for Dot1l In MLL -Rearranged Leukemia Using a Conditional Loss of Function Model

Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor

Lymphoma-Associated Mutations of EZH2 Result In a Change-of-Function

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

High Expression and Persistent Activation of STAT1, 3 and 5 Predicts Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Resistance in Cutaneous T-Cell Lymphoma Cells.

Identification of Informative Gene Expression Signatures Indicative of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Exposure and Clinical Efficacy in Patients with Advanced Cutaneous T-Cell Lymphoma.

Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Clinical Benefit to Advanced Cutaneous T-Cell Lymphoma Patients: Updated Results of the Phase IIb Multicenter Clinical Trial.

Clinical Responses to Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Are Associated with Specific Gene Expression Signatures in Patients with Advanced Leukemias: Results of a Phase I Trial.

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor

Phase I Clinical Trial of Oral Administration of the Histone Deacetylase (HDAC) Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Relapsed/Refractory Multiple Myeloma (MM).

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only